A subsidiary of French nanotechnology expert Nanobiotix, Curadigm, has been selected for the Sanofi iTech awards program, as a “highly promising option” to improve gene therapies. 26 January 2021
The US Food and Drug Administration has approved Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). 25 January 2021
French drugmaker Servier and UK-based MiNA Therapeutics have announced a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders. 21 January 2021
The National Institute for Health and Care Excellence (NICE) has published a final appraisal determination (FAD) recommending the use of the daily oral pill Jyseleca (filgotinib) on the National Health Service (NHS) in England for moderate to severe active rheumatoid arthritis (RA). 21 January 2021
California-based Gritstone Oncology saw its shares go stratospherical yesterday, closing up 248.5% at $22.27 and rising a further 19% after-hours, when the biotech firm announced encouraging progress on its COVID-19 vaccine candidate. 20 January 2021
Anglo-Irish rare diseases specialist Amryt Pharma (LSE: AMYT) has won a positive reimbursement decision in the UK for Myalepta (metreleptin). 20 January 2021
A subsidiary of US pharma major Eli Lilly and Dutch biotech Merus have announced a research collaboration and exclusive license agreement. 19 January 2021
US AAV-based gene therapies developer Taysha Gene Therapies today announced that it has received both rare pediatric disease and orphan drug designations from the US Food and Drug Administration for TSHA-105, an AAV9-based gene therapy in development for SLC13A5-related epilepsy. 19 January 2021
NewAmsterdam Pharma (NAP), a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, has completed an oversubscribed 160 million-euro ($196 million) Series A funding round. 14 January 2021
French pharma major Sanofi today revealed it has entered into an agreement under which it will acquire British privately-held biotech Kymab, which is focused on immune-mediated diseases and immuno-oncology therapeutics. 11 January 2021
US biotech DiCE Molecules, which is leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, has announced the completion of an $80 million Series C financing. 11 January 2021
Privately-held cell therapy developer ArsenalBio has entered into a multi-year discovery collaboration with Bristol Myers Squibb to advance next-generation T-cell therapies for the treatment of solid tumors. 8 January 2021
A2 Biotherapeutics has entered into an agreement with pharma giant Merck & Co, whereby A2 will continue research and pre-clinical development of its undisclosed Tmod cell therapy candidate. 24 December 2020
Sio Gene Therapies has reported positive six-month follow-up data from the low-dose cohort of the company’s dose escalation study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy for the treatment of GM1 gangliosidosis. 16 December 2020
UK provider of development services to drugmakers Ergomed today announced the acquisition of MS Clinical Services (MediSource), a specialized clinical research organization (CRO) based in Houston, Texas, USA. 14 December 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024